Rob L. H. Jansen

Wait-and-See Policy for Clinical Complete Responders After Chemoradiation for Rectal Cancer

Monique Maas, Geerard L. Beets, Doenja M. J. Lambregts et al. · Journal of Clinical Oncology · 2011 · 1.1K citations

Medicine, Oncology, Surgery +16

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Walter Taal, Hendrika M. Oosterkamp, Annemiek Walenkamp et al. · The Lancet Oncology · 2014 · 753 citations

Medicine, Oncology, Pharmacotherapy +16

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

Lieke H. J. Simkens, Harm van Tinteren, Anne M. May et al. · The Lancet · 2015 · 528 citations

Medicine, Oncology, Pharmacology +13

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man et al. · The Lancet Oncology · 2018 · 419 citations · Full text

Medicine, Oncology, Pharmacology +16

Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia‐associated invasive fungal infections

Alexander C. A. P. Leenders, Simon Daenen, Rob L. H. Jansen et al. · British Journal of Haematology · 1998 · 321 citations · Full text

Medicine, Infectious Diseases, Pharmacology +17